The Study of Cost-Effectiveness of Rivaroxaban versus Warfarin in Patients with Atrial Fibrillation Who Developed Ischemic Stroke

Table 2

Bleeding and ischemic stroke incidence of the AF patients treated with rivaroxaban and warfarin in 2019.

	Rivaroxaban		Warfarin	value
Sex(male/female)	Male	%62.1	%46.9	0.11
	Female	%37.9	%53.1
Mean age	66.7		65.1	0.72
CHADSVASC score	3.96		4.68	>0.05
Death	0		0	—
Mean of duration of medication	1	%67.2	%64.9	>0.05
	X > 1	%32.8	%35.1
Place of living	Village	%52.8	%37.5	0.06
	City	%47.2	%62.5
Illiterate	%52.4		%41.4	0.49
Ischemic stroke	%1.4		%4.3	>0.05
Hemorrhagic stroke	0		0	—
Myocardial infarction,	0		0	—
Intracranial hemorrhage	0		0	—
Life threatening nonintracranial hemorrhage	0		%2.8	0.31
Minor nonintracranial hemorrhage	Ecchymosis	%12.5	%36.1	<0.05
	Nosebleed	%2.8	%12.5
	Blood in urine and stool	%2.8	%4.2